ライフサイエンスコーパス: LDV

1 LDV 90 mg is currently being investigated in combination

2 LDV aerosol emissions were predominantly carbonaceous, a

3 LDV and SOF were evaluated using a fully factorial exper

4 LDV lightweighting increases total CM quantity per vehic

5 LDV-C-EPD infected mice as efficiently as did LDV-P, but

6 LDV-induced IFN-alpha had little effect on FV infection

7 LDV-permissive macrophages accumulated and supported the

8 LDV/SOF plus RBV was associated with a greater incidence

9 LDV/SOF without RBV is an effective and safe treatment o

10 veterans initiated therapy: 757 LDV/SOF, 138 LDV/SOF + RBV, 28 OPrD, and 73 OPrD + RBV.

11 Individual SVOC emissions from the Tier 2 LDVs and fuel technologies tested are substantially lowe

12 red with either treatment group (PrOD, 0.3%; LDV/SOF, 1.4%; untreated controls, 2.5%; P < .001).

13 rquartile range {IQR}, 0.08-0.30]; n = 372), LDV/SOF and TDF/PI (0.17 [IQR, 0.04-0.30]; n = 100), and

14 1-coinfected veterans initiated therapy: 757 LDV/SOF, 138 LDV/SOF + RBV, 28 OPrD, and 73 OPrD + RBV.

15 s contained a moderate number of LDVs (14.86 LDVs/microm2), some varicosities contained a large numbe

16 el ventilation air supply to derive accurate LDV source profiles incorporating three platinum group e

17 An LDV peptide-based small molecule that preferentially bin

18 to an ICAM-4-Fc construct is mediated by an LDV-inhibitable integrin on hemopoietic cells and an RGD

19 ilarity between the data we generated for an LDV ligand and published data for the RGD family support

20 Neither an unusual LETS nor an LDV motif in the first domain of ICAM-4 was critical for

21 he binding of a fluorescent derivative of an LDV peptide to several cell lines and leukocytes with al

22 Injection of such an LDV-C pool into mice of various strains resulted in the

23 ery late antigen-4 (VLA-4), measured with an LDV-containing small molecule, varies with cellular avid

24 TDF/PI (0.17 [IQR, 0.04-0.30]; n = 100), and LDV/SOF without TDF (0.15 [IQR, 0.00-0.30]; n = 423).

25 mpared with LDV 90 mg for 12 weeks (54%) and LDV 30 mg for 24 weeks (48%).

26 coexist in most available pools of LDV-C and LDV-P.

27 Sofosbuvir (400 mg once daily) and LDV (90 mg once daily) plus ribavirin (RBV) were given f

28 FV alone, those coinfected with both FV and LDV had delayed CD8(+) T-cell responses, as measured by

29 12 for participants treated with EBR/GZR and LDV/SOF with few adverse effects.

30 stinguish between ribavirin-free EBR/GZR and LDV/SOF.

31 With this assay, we found that LDV-P and LDV-C coexist in most available pools of LDV-C and LDV-P

32 ps given a fixed-dose combination of SOF and LDV, with RBV (n = 9) or without RBV (n = 10).

33 regions with significantly higher truck and LDV emissions.

34 95% CI: -6.3, 12.2) and between SOF/VEL and LDV/SOF (4.4, 95% CI: -2.4, 11.2).

35 a dynamic fleet analysis to determine annual LDV sales, scrappage, and fleet compositions.

36 ohydrate recognition domain (CRD) as well as LDV and RGD recognition sequences for integrin binding.

37 replication, with interferon-alpha blunting LDV viremia in the acute phase of the infection and inte

38 d with SOF resistance were not detected; but LDV-resistant mutants were selected and mutant subpopula

39 f LDV-C by LDV-P as the predominant LDV, but LDV-C also persisted in the mice at a low level along wi

40 displacement in the circulation of LDV-C by LDV-P as the predominant LDV, but LDV-C also persisted i

41 iferation, the immunosuppression mediated by LDV increased both the severity and the duration of FV i

42 us, lactate dehydrogenase-elevating virus C (LDV-C), competed with the SHFV 3'(-)209 RNA in competiti

43 ant opportunities for further characterizing LDV in order to study both failed immunity and the famil

44 Recently peptides containing a consensus LDV sequence based on the connecting segment-1 (CS-1) of

45 us mouse-passaged FV isolates also contained LDV and that coinfection with LDV delayed FV-specific CD

46 s been reported in gp120 proteins containing LDV/I, and the precise determinants of gp120-alpha4beta7

47 ype 1, an interferon-free regimen containing LDV/VDV/TGV/RBV was well tolerated and led to SVR12 in u

48 DV-C-EPD infected mice as efficiently as did LDV-P, but its level of viremia during the persistent ph

49 e freed LDV-C of LDV-P by endpoint dilution (LDV-C-EPD).

50 19-35 Mt/y in 2040 (2.5-4.7% of total direct LDV CO2 emissions).

51 l tracers of PM derived from gasoline-driven LDVs.

52 and NO2 anthropogenic increments, and either LDVs or area sources, the smallest.

53 (LDV) and SOF (LDV/SOF; LONESTAR, ELECTRON [LDV/SOF arms], ION1, ION2, and ION3), using deep sequenc

54 s as a technique to more accurately estimate LDVs' contributions to airborne PM.

55 he mechanism of this impairment, we examined LDV-induced innate immune responses and found LDV-specif

56 Existing LDVs would see more advanced spark timing and more effic

57 in HCV genotype-1 (GT-1) patients who failed LDV/SOF-containing therapy.

58 ond laser lenticule extraction (Ziemer FEMTO LDV Z8) produces good surface quality results.

59 ond laser lenticule extraction (Ziemer FEMTO LDV Z8).

60 First, LDV-induced IFN-gamma signaling indirectly modulated FV-

61 Recently, we described a fluorescent LDV-containing small molecule that was used to monitor V

62 Recently, we described a fluorescent LDV-containing small molecule, which we used to monitor

63 SVR rates were 91.3% (3,191/3,495) for LDV/SOF and 92.0% (527/573) for LDV/SOF+RBV (P = 0.65).

64 1/3,495) for LDV/SOF and 92.0% (527/573) for LDV/SOF+RBV (P = 0.65).

65 e glide paths provide long-term guidance for LDV powertrain/fuel development.

66 nt phase was only 1/10,000 that observed for LDV-P.

67 odified cost and performance projections for LDV technologies are adapted from the National Research

68 study uniquely evaluates U.S. CM demand for LDVs and MHDVs across conventional and electric powertra

69 Emission factors for LDVs and HDVs were calculated using a carbon balance met

70 to 2018, fleet-average emission factors for LDVs and HDVs, respectively, were found to decrease by 4

71 DV-induced innate immune responses and found LDV-specific induction of IFN-alpha and IFN-gamma.

72 We have freed LDV-C of LDV-P by endpoint dilution (LDV-C-EPD).

73 conomy, and CO2 emission benefits for future LDVs through higher compression ratios for different ass

74 However, researchers were unable to grow LDV in culture, ultimately resulting in the demise of th

75 the conditions under which EDVs achieve high LDV market penetration in the U.S. and quantify the asso

76 to BAU, OPT gives 16% and 36% reductions in LDV greenhouse gas (GHG) emissions for 2030 and 2050, re

77 created with a low-energy femtosecond laser (LDV Z8; Ziemer Ophthalmic Systems, Port, Switzerland) an

78 Ledipasvir (LDV)/sofosbuvir (SOF) has demonstrated high efficacy, sa

79 entify drug interactions between ledipasvir (LDV) and sofosbuvir (SOF) against a genotype 1b replicon

80 25) and 5 studies of combination ledipasvir (LDV) and SOF (LDV/SOF; LONESTAR, ELECTRON [LDV/SOF arms]

81 ir (SOF) with the NS5A inhibitor ledipasvir (LDV) or the NS5B non-nucleoside inhibitor GS-9669 in pat

82 uctural protein (NS)5A inhibitor ledipasvir (LDV), NS3 protease inhibitor vedroprevir (VDV), non-nucl

83 essed the efficacy and safety of ledipasvir (LDV) and sofosbuvir (SOF) for 12 weeks in HCV genotype-1

84 ssess the efficacy and safety of ledipasvir (LDV)-SOF plus RBV in patients with genotype 1 hepatitis

85 uated the safety and efficacy of ledipasvir (LDV)-sofosbuvir (SOF) in treating HCV genotype-4 infecte

86 arly the use of sofosbuvir (SOF)/ledipasvir (LDV) without RBV in this patient population.

87 to determine the emission factors for light (LDV) and heavy-duty vehicles (HDV).

88 tic acid-valine-proline (BIO1211) as a model LDV-containing ligand to study alpha4beta1 integrin-liga

89 V2) of gp120, including the tripeptide motif LDV/I, are thought to mediate gp120-alpha4beta7 binding.

90 ic infection models in the laboratory mouse, LDV infection may be useful for exploring unique modes o

91 iffers about 60% between the neuropathogenic LDV-C and the nonneuropathogenic LDV-P, we have develope

92 Therefore, although neuropathogenic LDVs possess the unique ability to infect anterior horn

93 e and others have found that neuropathogenic LDVs fail to retain their neuropathogenicity during pers

94 opathogenic LDV-C and the nonneuropathogenic LDV-P, we have developed a reverse transcription-PCR ass

95 We have freed LDV-C of LDV-P by endpoint dilution (LDV-C-EPD).

96 the rapid displacement in the circulation of LDV-C by LDV-P as the predominant LDV, but LDV-C also pe

97 ost-effective was 13 and the maximum cost of LDV/SOF therapy at which treatment before LT is cost-eff

98 Effects of LDV operating conditions and ambient temperature (-7 and

99 Use of RBV did not impact the efficacy of LDV/SOF regimens in the ION phase III studies.

100 We present the first evaluation of LDV emissions while hauling cargo, showing that carrying

101 cell-culture systems, enabling the growth of LDV in immortalized cell lines for the first time.

102 ple, various plasma pools of 10(9.5) ID50 of LDV-C/ml contained about 10(5) ID50 of LDV-P/ml.

103 50 of LDV-C/ml contained about 10(5) ID50 of LDV-P/ml.

104 little as 10 50% infectious doses (ID50) of LDV.

105 aim of this study was to model the impact of LDV/SOF (ledipasvir/sofosbuvir), the first Peg-IFN- and

106 2) was higher in patients receiving 90 mg of LDV for 24 weeks (63%), compared with LDV 90 mg for 12 w

107 n part to a more efficient neutralization of LDV-C than LDV-P by antibodies to the primary envelope g

108 and LDV-C coexist in most available pools of LDV-C and LDV-P.

109 C(50) for HUTS-21 binding in the presence of LDV was identical to a previously reported ligand equili

110 mpare the safety and tolerability profile of LDV-SOF with and without RBV.

111 The specific suppression of LDV-C replication in persistently infected mice is proba

112 assess sustained virologic response (SVR) of LDV/SOF+/-ribavirin (RBV) in routine medical practice.

113 eceived the fixed-dose combination tablet of LDV-SOF once-daily plus weight-based RBV (1,000 or 1,200

114 but also maximizing the clinical utility of LDV and SOF combination regimens.

115 Twelve weeks of LDV-SOF plus RBV was an effective and safe treatment for

116 for relapse between 8 weeks and 12 weeks of LDV/SOF (relative risk = 0.99, 95% confidence interval 0

117 1-coinfected veterans initiating 12 weeks of LDV/SOF +/- RBV or OPrD +/- RBV.

118 rds on patients taking 8, 12, or 24 weeks of LDV/SOF +/- ribavirin (RBV).

119 to determine the effectiveness of 8 weeks of LDV/SOF treatment, examine variables associated with rel

120 the effectiveness of 8 weeks and 12 weeks of LDV/SOF treatment.

121 fibrosis who previously failed 4-6 weeks of LDV/SOF with GS-9669 and/or GS-9451 received LDV/SOF for

122 ho were randomized to 8, 12, and 24 weeks of LDV/SOF with or without RBV.

123 e a high SVR rate in response to 12 weeks of LDV/SOF, even for patients with NS5A resistance-associat

124 varicosities contained a moderate number of LDVs (14.86 LDVs/microm2), some varicosities contained a

125 ome varicosities contained a large number of LDVs, whereas others contained very few.

126 We identified 1473 persons on PrOD, 5497 on LDV/SOF, and 6970 propensity score-matched untreated per

127 em and lymphocytes-had very little impact on LDV infection.

128 ind that interferons have a modest impact on LDV replication, with interferon-alpha blunting LDV vire

129 g-knockout mice, had only a modest impact on LDV viremia, and only during the sub-acute phase of infe

130 Renal function did not worsen on LDV/SOF regimens with TDF.

131 weeks (N = 654) with LDV/SOF (N = 1,080) or LDV/SOF+RBV (N = 872).

132 LDV 30 mg once daily (QD; Arm 1; n = 46) or LDV 90 mg QD (Arm 2; n = 94); patients in both arms also

133 rticipants who received 1 dose of EBR/GZR or LDV/SOF ( ribavirin), SVR12 was 95.2% (95% CI, 92.8%-97.

134 Treatment with PrOD or LDV/SOF and SVR are associated with a significant mortal

135 ed HCV-infected persons initiated on PrOD or LDV/SOF, excluding those with human immunodeficiency vir

136 ulation of LDV-C by LDV-P as the predominant LDV, but LDV-C also persisted in the mice at a low level

137 imen with very high viral eradication rates (LDV/SOF) would translate to annual productivity loss sav

138 received LDV/SOF with RBV and 1,080 received LDV/SOF alone) were analyzed.

139 ta from 1,952 patients (of whom 872 received LDV/SOF with RBV and 1,080 received LDV/SOF alone) were

140 LDV/SOF with GS-9669 and/or GS-9451 received LDV/SOF for 12 weeks.

141 Patients received LDV/SOF (90-400 mg) once daily for 12 to 24 weeks with o

142 The majority of patients received LDV/SOF with or without ribavirin (91%) and were treated

143 ange did not differ among patients receiving LDV/SOF and tenofovir disoproxil fumarate (TDF) without

144 Patients receiving LDV/SOF regimens showed significant improvement of PRO s

145 concomitant medications than those receiving LDV/SOF alone.

146 eiving GLE/PIB compared with those receiving LDV/SOF, indicating that GLE/PIB may merit further inves

147 the infection and interferon-gamma reducing LDV viral loads in the chronic phase of infection, but o

148 pasvir/sofosbuvir with or without ribavirin (LDV/SOF +/- RBV) and ombitasvir/ paritaprevir/ritonavir

149 We examine how 2021-2050 U.S. LDV cumulative emissions can be limited to 23.1 Gt CO(2e

150 emissions and economic impacts for the U.S. LDV fleet are estimated based on a linear-programming re

151 Without aggressive actions, U.S. LDVs will likely exceed the cumulative emissions budget

152 lobal temperature rises attributable to U.S. LDVs.

153 and disposal emissions attributable to U.S. LDVs.

154 rmationally sensitive antibodies and a small LDV-containing ligand to study the role of the inside-ou

155 ies of combination ledipasvir (LDV) and SOF (LDV/SOF; LONESTAR, ELECTRON [LDV/SOF arms], ION1, ION2,

156 Of TN patients receiving 6 weeks of SOF, LDV, and RBV, 17 of 25 (68%) achieved SVR12.

157 inally, a group of TN patients received SOF, LDV, and RBV for 6 weeks (n = 25).

158 SVR12-9 of 9 (100%) of those receiving SOF, LDV, and RBV and 10 of 10 (100%) of those receiving SOF,

159 y 25 of 25 (100%) TN patients receiving SOF, LDV, and RBV and 23 of 25 (92%) of those receiving SOF,

160 achieved by 9 (100%) of those receiving SOF, LDV, and RBV and 7 (70%) of those receiving SOF and LDVD

161 SOF/LDV without RBV was used for 12 weeks in patients with e

162 med to assess the efficacy and safety of SOF/LDV fixed-dose combination without RBV in patients with

163 The combination of SOF/LDV without RBV for 12 or 24 weeks produced 100% SVR 12

164 ng a third DAA to ledipasvir and sofosbuvir (LDV/SOF) can result in high SVR rates in patients withou

165 ents treated with ledipasvir and sofosbuvir (LDV/SOF) with and without RBV.

166 sofosbuvir (SOF) and ledipasvir/sofosbuvir (LDV/SOF) based regimens.

167 ght weeks duration of ledipasvir/sofosbuvir (LDV/SOF) can be considered in genotype 1 hepatitis C vir

168 The uptake of ledipasvir/sofosbuvir (LDV/SOF) regimens across health care settings has been r

169 dasabuvir (PrOD) and ledipasvir/sofosbuvir (LDV/SOF) regimens upon mortality.

170 rance likely to cover ledipasvir/sofosbuvir (LDV/SOF) were recruited from 34 US viral hepatitis clini

171 patients treated with ledipasvir/sofosbuvir (LDV/SOF) were significantly less likely to achieve cure

172 combination tablet of ledipasvir/sofosbuvir (LDV/SOF) with and without ribavirin (RBV) resulted in hi

173 g concomitant PPI and ledipasvir/sofosbuvir (LDV/SOF).

174 SOF/VEL; n = 54), and ledipasvir/sofosbuvir (LDV/SOF; n = 145).

175 the efficient replication of superinfecting LDV-P.

176 D-1 showed no signs of disease and supported LDV viral loads at levels equivalent to their wild-type

177 00 ng/ml of SOF must be attained to suppress LDV-resistant subpopulations.

178 more efficient neutralization of LDV-C than LDV-P by antibodies to the primary envelope glycoprotein

179 s as well as concomitant medication use than LDV/SOF alone.

180 With this assay, we found that LDV-P and LDV-C coexist in most available pools of LDV-C

181 Altogether, these findings imply that LDV uses a unique and highly effective mechanism to avoi

182 The findings reveal that LDVs dominate the total CM demand despite MHDVs requirin

183 The LDV-induced suppression was not mediated by T regulatory

184 ve for the total replicon population and the LDV-resistant population, but a threshold concentration

185 hods, the L-type current was enhanced by the LDV but not LEV peptide and was blocked by PP2 or antibo

186 we synthesized cyclopeptides containing the LDV recognition motif found in the native ligand fibrone

187 ing an 80% emission reduction target for the LDV sector.

188 have little effect on GHG emissions from the LDV sector but are more effective in the electricity sec

189 wn to be located in similar positions in the LDV-C 3'(-)NCR and SHFV 3'(-)209 RNAs.

190 The structure/activity relationship of the LDV sequence is discussed and related to the recently pu

191 concentration of a peptide consisting of the LDV sequence of the fibronectin connecting segment, Ac-L

192 A series of cyclized peptides based on the LDV sequence of CS1 were synthesized and assayed for inh

193 er and mammary epithelial cells and that the LDV peptide represses PHSRN-stimulated MMP-1 production

194 nd to the SHFV 3'(-)209 RNA also bind to the LDV-C 3'(-)NCR RNA and equine arteritis virus 3'(-)NCR R

195 Patients were randomized 1:2 to LDV 30 mg once daily (QD; Arm 1; n = 46) or LDV 90 mg QD

196 Adding a third DAA to LDV/SOF may result in a moderate SVR rate, lower than th

197 Participants were randomized ( ribavirin) to LDV/SOF, elbasvir/grazoprevir (EBR/GZR), and paritaprevi

198 GLE/PIB was superior to LDV/SOF, with a mean difference in improvement of 7.3 po

199 concentration-dependent vasoconstriction to LDV peptides but not to Leu-Glu-Val (LEV) control peptid

200 distinguishes between the genomes of the two LDVs and detects as little as 10 50% infectious doses (I

201 ction or immune responses, but unexpectedly, LDV-induced IFN-gamma production dampened Th1 adaptive i

202 om a societal perspective, HCV therapy using LDV/SOF with ribavirin before LT is the most cost-effect

203 in with peptides containing the Leu-Asp-Val (LDV) integrin--binding sequence, which is found in the C

204 rs of alpha4beta1, based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting

205 ntly described leucine-aspartic acid-valine (LDV)-based small molecule inhibitor of alpha4beta1 (BIO-

206 to spatially distribute light-duty vehicle (LDV) and heavy-duty truck emissions across the city of T

207 ion to meet growing U.S. light duty vehicle (LDV) demand.

208 sion reductions from the light-duty vehicle (LDV) fleet consistent with stabilization of atmospheric

209 s (GHG) emissions of the light-duty vehicle (LDV) fleet could differ by an average of 21% (5-43% rang

210 0.7 V under traditional light-duty vehicle (LDV) H(2)-air conditions (150 kPa(abs) and 0.10 mg(Pt) c

211 ric vehicles into the US light duty vehicle (LDV) sector.

212 1, light duty vehicle-low emission vehicle (LDV-LEV), light duty truck 2-LEV (LDT2-LEV), and Tier 2

213 G) emissions of current light-duty vehicles (LDV) across powertrains, vehicle classes, and locations.

214 , and disposing of U.S. light-duty vehicles (LDVs) account for 3% of global greenhouse gas emissions

215 y that is restricted to light-duty vehicles (LDVs) and (2) inverse dispersion model calculations.

216 gasoline + ethanol for light-duty vehicles (LDVs) and diesel + biodiesel for heavy-duty vehicles (HD

217 the U.S. CM demand for light-duty vehicles (LDVs) and medium- and heavy-duty vehicles (MHDVs).

218 ng advanced controls on light-duty vehicles (LDVs) and other sources.

219 emission compliance of Light Duty Vehicles (LDVs) around the world and to establish the reference ve

220 Light-duty vehicles (LDVs) in the United States and elsewhere are required to

221 -fueled privately owned light duty vehicles (LDVs) operated in Tehran.

222 efits of designing U.S. light-duty vehicles (LDVs) to attain higher fuel economy by utilizing higher

223 inantly gasoline-driven light-duty vehicles (LDVs) traversing the Washburn Tunnel in Houston, Texas d

224 ted from three light-duty gasoline vehicles (LDVs) operating on gasoline (e0) and ethanol-gasoline fu

225 esicles (CLV) and large dense core vesicles (LDV).

226 ) and lactate dehydrogenase-elevating virus (LDV) are endemic mouse viruses that can cause long-term

227 es of lactate dehydrogenase-elevating virus (LDV) differ from nonneuropathogenic isolates in their un

228 with lactate dehydrogenase-elevating virus (LDV) impairs early adaptive immune responses to Friend v

229 irus, lactate dehydrogenase-elevating virus (LDV), was discovered and found to have the peculiar abil

230 tence-lactate dehydrogenase-elevating virus (LDV)-and use modern transgenic mouse technologies to inv

231 tion (lactate dehydrogenase-elevating virus, LDV) and applied modern tools of mouse immunology to fur

232 immunity and the family of viruses to which LDV belongs, Arteriviridae (aka, arteriviruses).

233 While LDV did not alter the type of acute pathology induced by

234 d substantially between 2019 and 2020 whilst LDVs decreased.

235 1), 12 (N = 867), or 24 weeks (N = 654) with LDV/SOF (N = 1,080) or LDV/SOF+RBV (N = 872).

236 sisted in the mice at a low level along with LDV-P.

237 also contained LDV and that coinfection with LDV delayed FV-specific CD8(+) T-cell responses during a

238 mg of LDV for 24 weeks (63%), compared with LDV 90 mg for 12 weeks (54%) and LDV 30 mg for 24 weeks

239 not only in mice infected concomitantly with LDV but also in mice chronically infected with LDV 8 wee

240 V but also in mice chronically infected with LDV 8 weeks prior to infection with FV.

241 Coinfection of mice with LDV and FV provides a well-defined, natural host model f

242 1 did not affect the treatment outcome with LDV/SOF.

243 uctivity, treatment of CHC GT1 patients with LDV/SOF-based regimens is likely to result in significan

244 In this real-world cohort, SVR rates with LDV/SOF+/-RBV nearly matched the rates reported in clini

245 Patients receiving RBV with LDV/SOF were more likely to require dose modification, i

246 IFN- and RBV-free regimens with LDV/SOF result in early HCV suppression with simultaneou

247 Of patients treated with LDV, SOF, and the NS3/4A protease inhibitor GS-9451 for

248 ment in HCV genotype 1 patients treated with LDV/SOF+/-RBV (ION-1, -2, and -3).

249 nt-naive, HCV-infected veterans treated with LDV/SOF+/-RBV.

250 1,979 patients with chronic HCV treated with LDV/SOF.

251 Intensification of SOF treatment with LDV reduced the emergence of L159F or V321A to 2% (1 of

252 An 8-week duration of treatment with LDV/SOF is highly effective in properly selected patient

253 On the other hand, during treatment with LDV/SOF+RBV, PRO scores declined (up to -5.5% regardless

254 PPI use with LDV/SOF +/- RBV did not affect SVR (89.7% [131/146] with

255 African American race or PPI use with LDV/SOF +/- RBV was not associated with lower SVR rates,

256 , 634 patients were treated for 8 weeks with LDV/SOF, of whom all had outcomes of cure or relapse wit